Presented at CMSC Annual Meeting 2022 • June 1–4, 2022 • National Harbor, MD, USA

Ofatumumab Improves NEDA-3 Likelihood in Hispanic/Latino **Patients Compared With Teriflunomide in Relapsing Multiple** Sclerosis: Subgroup Analysis of the ASCLEPIOS Studies

Silvia R. Delgado,¹ Lilvana Amezcua,² Stanley L. Cohan,³ Jeffrey A. Cohen,⁴ Le H. Hua,⁵ Elisabeth Lucassen,⁶ Xiangyi Meng,⁶ Mitzi J. Williams,⁷ James Stankiewicz⁶

¹Department of Neurology, University of Miami Miller School of Medicine, Miami, FL, USA; ²University of Southern California, Los Angeles, CA, USA; ³Providence Multiple Sclerosis Center, Providence Brain and Spine Institute, Portland, OR, USA; ⁴Cleveland Clinic Mellen Center, Cleveland, OH, USA; ⁵Lou Ruvo Center for Brain Health, Las Vegas, NV, USA; ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; ⁷Joi Life Wellness MS Center, Atlanta, GA, USA

SUMMARY

- This post hoc analysis assessed the proportion of patients with RMS who achieved NEDA-3 in the Hispanic/Latino and White subgroups of 2 large, randomized, double-blind, phase 3 clinical trials of ofatumumab vs teriflunomide
- 45% of Hispanic and Latino patients undergoing of atumumab treatment and 23% undergoing teriflunomide treatment achieved NEDA-3 during the full trial course. with ofatumumab providing an ~3-fold increase in the odds of achieving NEDA-3
- **94%** of Hispanic and Latino patients undergoing of atumumab treatment and **59%** undergoing teriflunomide treatment achieved NEDA-3 when assessing Months 12 to 24, with ofatumumab providing an ~12-fold increase in the odds of achieving NEDA-3



Scan to download a copy of this poster Copies of this poster and its content, obtained through this QR code, are for personal use only and may not be reproduced without written rmission from the authors



INTRODUCTION

- Hispanic and Latino persons with multiple sclerosis (MS) have been reported to experience greater disease severity and more rapid progression than White people²⁻⁴
- Ofatumumab, a fully human anti-CD20 monoclonal antibody, is approved by the US Food and Drug Administration for the treatment of adults with relapsing MS (RMS)
- ASCLEPIOS I and II were randomized, double-blind, phase 3 trials of subcutaneous ofatumumab vs oral teriflunomide in patients with RMS⁶
- Previous analysis of ASCLEPIOS results in a Hispanic and Latino subgroup found that relapse rate reduction, pharmacokinetics/pharmacodynamics, and safety outcomes were similar to the overall trial population⁷

OBJECTIVES

RESULTS

PATIENTS

Table 1. Baseline Characteristics

Characteristi Shown as mean±

Age, years

Female, n (%)

Race, n (%)

Black/African Arr

White

Other

Hispanic/Latino eth

MS duration since

Number of relapse

EDSS score, medi

T2 lesion volume,

Free of Gd+ T1 les

Number of Gd+ T1

"Unknown." or "Other"

ABBREVIATIONS: AE, adverse event; CI, confidence interval; **D**, day; **EDSS**, Expanded Disability Status Scale; **EOS**, end of study;

- Minority groups are persistently underrepresented in clinical trials, resulting in limited data to inform clinical decision-making for these patients¹
- Patients with MS of Spanish-speaking heritage have varying racial and ethnic backgrounds and genetic differences that may influence treatment effectiveness^{4,5}

To report findings of a post hoc analysis from the phase 3 ASCLEPIOS I and II studies assessing achievement of 3-parameter no evidence of disease activity (NEDA-3) with ofatumumab vs teriflunomide in a subgroup of patients with RMS who identified as Hispanic or Latino and to compare findings with those of White patients

 Of 1882 patients in the overall ASCLEPIOS population, 147 (7.8%) identified as Hispanic/Latino and 1658 (88.1%) as White (122 patients were included in both subgroups)

- Hispanic/Latino patients had larger T2 lesion volume; otherwise, baseline characteristics were similar across subgroups (**Table 1**)

	Hispanic	:/Latino*	White			
or n (%)	Teriflunomide (n=71)	Ofatumumab (n=76)	Teriflunomide (n=829)	Ofatumumab (n=829)		
	37.8±9.2	37.5±9.6	38.3±9.3	38.5±9.0		
	48 (67.6)	50 (65.8)	561 (67.7)	555 (67.0)		
merican	0	2 (2.6)	0	0		
	59 (83.1)	63 (82.9)	829 (100)	829 (100)		
	11 (15.5)	11 (14.5)	0	0		
thnicity, n (%)	71 (100)	76 (100)	59 (7.1)	63 (7.6)		
e diagnosis, years	5.06±4.97	5.86±6.05	5.57±6.18	5.76±6.36		
es in last 12 months	1.20±0.58	1.18±0.65	1.28±0.73	1.26±0.71		
lian (range)	2.50 (1.0-5.5)	3.00 (0.0-6.0)	2.50 (0.0-6.5)	3.00 (0.0-6.0)		
cm ³	14.29±15.50	16.42±16.21	12.32±13.85	13.29±13.71		
sions, n (%)	47 (66.2)	42 (55.3)	519 (62.6)	498 (60.1)		
1 lesions	1.2±3.0	3.0±6.1	1.3±3.5	1.6±4.6		

EDSS, Expanded Disability Status Scale; Gd+, gadolinium-enhancing; MS, multiple sclerosis; SD, standard deviation *The Hispanic/Latino and White subgroups are not mutually exclusive. †Includes patients selecting "Native American," "Pacific Islander,"

METHODS


STUDY DESIGN

- This analysis pooled data from the ASCLEPIOS I and II studies (ClinicalTrials.gov identifiers, NCT02792218 and NCT02792231), which had identical study designs (Figure 1)
- Patients received injections of ofatumumab 20 mg or oral teriflunomide 14 mg for up to 30 months

ANALYSES

- NEDA-3 was analyzed via a logistic regression model in a modified full analysis set⁸ - NEDA-3 was defined as no 6-month confirmed disability worsening (based on Expanded Disability Status Scale), no confirmed MS relapse, no new/enlarging T2 lesions, and no gadolinium-enhancing T1 lesions
- Race and ethnicity were self-reported by patients
- Race categories included Black/African American (patients who selected "Black" as race), White (selecting "Caucasian"), and Other (selecting "Native American," "Pacific Islander," "Unknown," or "Other")
- Separately, patients reported their ethnicity as Hispanic or Latino (termed) Hispanic/Latino in this poster) or not Hispanic or Latino
- NEDA-3 outcomes were compared between treatment groups (within the Hispanic/Latino) and White subgroups) via Fisher's exact test
- Hypothesis generation without adjustment for multiple comparison
- Rates of adverse events (AEs) were also reported

Figure 2. Achievement of NEDA-3



CI, confidence interval; mFAS, modified full analysis set; N', patients available for analysis; NEDA, 3-parameter no evidence of disease activity; OR, odds ratio The mFAS used for NEDA calculations consisted of all patients in the FAS, except those who discontinued from study drug prematurely for reasons other than 'lack of efficacy' or 'death' and had NEDA before early discontinuation. Patients who discontinued from study drug prematurely for reasons 'lack of efficacy' or 'death' were considered as having evidence of disease activity in the analysis (even if no evidence of disease activity was reported)

ACHIEVEMENT OF NEDA-3

- In both the Hispanic/Latino and White subgroups, ofatumumab increased the odd achieving NEDA-3 vs teriflunomide during Months 0 to 12 by ~3-fold in both group (Figure 2A), Months 12 to 24 by ~12- and 8-fold, respectively (Figure 2B), and Months 0 to 24 by ~3-fold in both groups (**Figure 2C**)
- In patients treated with of atumumab, achievement of NEDA-3 was consistent the Hispanic/Latino and White subgroups

SAFETY

- Rates of AEs, serious AEs, and AEs resulting in discontinuation were balanced I ofatumumab and teriflunomide in each patient subgroup (Table 2)
- There were no significant differences in types of reported AEs between subgroup
- Serious AEs of appendicitis occurred in 3 Hispanic/Latino patients treated with ofatumumab


ACKNOWLEDGMENTS: The study was supported by Novartis Pharmaceuticals Corporation. Medical writing support was provided by Lisa Baker, PhD, of Envision Corporation. This poster was developed in accordance with Good Publication Practice (GPP3) guidelines. Authors had full control of the content and made the final decision on all aspects of this poster

DISCLOSURES: Silvia R. Delgado has received consultant fees from Novartis, and research grant funding (clinical trials) from EMD Serono, MAPI Pharma, National MS Society, NIH/NINDS, and Novartis. Lilyana Amezcua has received personal compensation for serving as a consultant for Biogen, Novartis, and Serono, and for serving on a scientific advisory or data safety monitoring board for Genentech. Her institution has received research support from Bristol Myers Squibb Foundation, Genentech, MedDay, National MS Society, and NIH/NINDS. Stanley L. Cohan has served on advisory boards or steering Pharma Group and was funded by Novartis Pharmaceuticals committees for AbbVie, Biogen, EMD Serono, Novartis, Roche/Genentech, and Sanofi Genzyme; has received research support from Adamas, Biogen, EMD Serono, MedDay, Novartis, Opexa, Roche/Genentech, and Sanofi Genzyme; and has received speaker honoraria from Biogen, Bristol Myers Squibb, Roche/Genentech, and Sanofi Genzyme. Jeffrey A. Cohen has received personal compensation for consulting from Adamas, Atara, Bristol Myers Squibb, Convelo, MedDay, and Mylan, and for serving as an editor of Multiple Sclerosis journal. Le H. Hua received personal fees for speaking, consulting, and advisory board activities from Biogen, Celgene, EMD Serono, Genentech, Genzyme, and Novartis. Elisabeth Lucassen, Xiangyi Meng, and James Stankiewicz are employees of Novartis. Mitzi J. Williams has received consulting/speaking fees from AbbVie, Alexion, Biogen, Bristol Myers Squibb, EMD Serono, Genentech, Janssen, Novartis, and Sanofi Genzyme, and research support from Biogen, Genentech, and Novartis

REFERENCES: 1. Avasarala J et al. *CNS Spectr*. Published online February 10, 2021. https://doi.org/10.1017/S1092852921000183. 2. Kister I et al. Neurol Clin Pract. 2021;11(4):335-341. 3. Ventura RE et al. *Mult Scler.* 2017;23(11):1554-1557. 4. Aguirre-Cruz L et al. Autoimmunity. 2011;44(7):571-575. 5. Beecham AH et al. Mult available for analysis; **NEDA-3**, 3-parameter no Scler. 2020;26(11):1329-1339. 6. Hauser SL et al. N Engl J Med. evidence of disease activity; **OR**, odds ratio; **PBO**, 2020;383(6):546-557. 7. Delgado SR et al. *Neurology*. 2021;96(15 placebo; **RMS**, relapsing multiple sclerosis; **s.c.**, suppl):4139. 8. Gärtner J, et al. *Mult Scler*. Published online March 10, 2022. doi: 10.1177/13524585221078825.

Gd+, gadolinium-enhancing; mFAS, modified full analysis set; **MS**, multiple sclerosis; **N**', patients subcutaneous; **SD**, standard deviation; **W**, week

Figure 1. Study Design of ASCLEPIOS I and I



D, day; EDSS, Expanded Disability Status Scale; EOS, end of study; PBO, placebo; RMS, relapsing multiple sclerosis; s.c., subcutaneous;

Table 2. Summary of AEs

lds of ups		Hispanic/Latino		White	
between	Event, n (%)	Teriflunomide (n=71)	Ofatumumab (n=76)	Teriflunomide (n=829)	Ofatumumab (n=829)
	Any AE	61 (85.9)	61 (80.3)	697 (84.1)	704 (84.9)
between	Any serious AE	6 (8.5)	5 (6.6)	67 (8.1)	78 (9.4)
	Any AE resulting in discontinuation	6 (8.5)	6 (7.9)	44 (5.3)	52 (6.3)
oups	Any serious infection	2 (2.8)	3 (4.0)	16 (1.9)	19 (2.3)
ו	AE, adverse event				